PROCRITLine.com

Portal Home

For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.

PROCRITline.com Reimbursement Excellence

State Medicare Guidelines / CMS 1500

Resources to help patients or caregivers learn more about treatments or financial programs.

Publications and toolkits for billing professionals regarding reimbursement issues and processes.

Over 400 links to societies and state sites that will help with reimbursement, insurance or specific patient needs.

PROCRIT^® (Epoetin alfa) is marketed by Centocor Ortho Biotech Products, L.P.

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT^® (Epoetin alfa).
The Boxed WARNINGS are shown below.

PROCRIT^® Guidelines Updated in August '10
- Updated state guidelines for Medicare Part B include: CA, HI, NV. Click here.
Prior Authorization Info
- Commercial Payer
- Medicare Part D
Physician Fee Schedule Changes for 2010
- On October 30, 2009, the Centers for Medicare & Medicaid Services (CMS) released the Calendar Year (CY) 2010 Medicare Physician Fee Schedule (MPFS) Final Rule. For more information click here.
Medicare OPPS for 2010
- Most separately payable Medicare Part B-covered drugs that are administered by physicians in the hospital outpatient setting will be reimbursed at a rate of ASP plus 4% in 2010. For more information click here.
Voluntary Recall Notice
- Press Release and Healthcare Professional Letter
Carrier/FI/MAC Changes
- The Centers for Medicare & Medicaid Services (CMS) is integrating the administration of Medicare Parts A and B for the fee-for-service benefit to new entities called Medicare Administrative Contractors (MACs). To learn more about the status of this program in your state, click here
Subscribe to E-mail Alert Service
- Sign up for our e-mail alert service that will let you know when PROCRITline.com has summary guideline updates, new information or features. This service will keep you on top of the latest changes here at PROCRITline.com. To subscribe click here.

MedicareRx - Prescription Drug Coverage - Click Here to Learn More

Important Safety Information for PROCRIT^® (Epoetin alfa)

WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE

Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious cardiovascular events, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 13 g/dL and above.

Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1).

To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.

Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT^® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT^® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

(See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT^® (Epoetin alfa)

Medication Guide for PROCRIT^®
Please read the Medication Guide for PROCRIT^® and discuss with your doctor.

Patient Instructions for Use
Instructions if you or your caregiver has been trained to give PROCRIT^® injections at home.